Get Level 2
Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. EMTN Programme Routine Technical Update

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes
Get Live Data
13,858.00    304.00 (2.24%)
Bid:
13,842.00
Ask:
13,846.00
Spread: 4.00 (0.029%)
Market Cap: £214.92b
AZN Live PriceLast checked at - London Stock Exchange

Intraday Astrazeneca Share Chart

EMTN Programme Routine Technical Update

11 Jun 2020 07:00

RNS Number : 6000P
AstraZeneca PLC
11 June 2020
 

11 June 2020 07:00 BST

 

EMTN Programme Routine Technical Update: Publication of Prospectus

 

Following a routine technical update of the Company's Euro Medium Term Note ("EMTN") programme established in 2007, the following prospectus has been approved by the Financial Conduct Authority and is available for viewing:

 

Base Prospectus for the AstraZeneca PLC U.S. $10,000,000,000 Euro Medium Term Note Programme (the "Prospectus").

 

The last drawdown under the EMTN programme was in 2016.

 

To view the full document, please paste the following URL into the address bar of your browser.

 

http://www.rns-pdf.londonstockexchange.com/rns/6000P_1-2020-6-10.pdf

 

A copy of the above Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at:

 

http://www.morningstar.co.uk/uk/NSM

 

 

 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.

 

Contacts

For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
PDIFLFFARAIILII
151617181920212223
Date   Source Headline
24th Apr 20187:00 amRNSIssue of Equity - AstraZeneca
19th Apr 20187:00 amRNSFDA approves Tagrisso for 1st-line use in NSCLC
13th Apr 201811:00 amRNSNotice of AGM
5th Apr 20187:00 amRNSDirectorate Change
3rd Apr 20183:00 pmRNSTotal Voting Rights
3rd Apr 20187:00 amRNSFDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
3rd Apr 20187:00 amRNSAZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
28th Mar 20183:00 pmRNSDirector/PDMR Shareholding
26th Mar 20183:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20184:48 pmRNSLokelma approved in the EU
12th Mar 20187:00 amRNSASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
7th Mar 20187:00 amRNSFiling of Form 20-F with SEC
6th Mar 201811:00 amRNSAnnual Financial Report
1st Mar 20183:00 pmRNSTotal Voting Rights
23rd Feb 201812:35 pmRNSLynparza CHMP for ovarian cancer maintainance
19th Feb 20187:00 amRNSAstraZeneca's IMFINZI approved for Stage III nsclc
15th Feb 20187:00 amRNSSelumetinib in NF1 gets FDA orphan drug status
5th Feb 20182:00 pmRNSDirector/PDMR Shareholding
2nd Feb 20187:00 amRNSAZN: Full-Year 2017 Results
1st Feb 20183:00 pmRNSTotal Voting Rights
26th Jan 20186:20 pmRNSAZ Reports Phase III Results for PT010 in COPD
26th Jan 20187:00 amRNSAZ Reports Phase III Results for PT010 in COPD
19th Jan 20187:00 amRNSASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
19th Jan 20187:00 amRNSLYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
12th Jan 20184:10 pmRNSFDA approves Lynparza for metastatic breast cancer
10th Jan 20183:10 pmRNSAstraZeneca's Fasenra approved in the EU
2nd Jan 20183:00 pmRNSTotal Voting Rights
28th Dec 20172:00 pmRNSDirector/PDMR Shareholding
18th Dec 20177:00 amRNSFDA accepts Tagrisso submission for 1st-line nsclc
15th Dec 201712:00 pmRNSDirector/PDMR Shareholding
1st Dec 20173:00 pmRNSTotal Voting Rights
1st Dec 20173:00 pmRNSBlock listing Interim Review
28th Nov 20177:00 amRNSEMA accepts Tagrisso submission for 1st-line nsclc
27th Nov 20177:00 amRNSAZ submits Tagrisso in Japan for 1st-line nsclc
15th Nov 20177:00 amRNSAZ Fasenra receives FDA approval for severe asthma
10th Nov 201711:35 amRNSBENRALIZUMAB POSITIVE CHMP IN EOSINOPHILIC ASTHMA
9th Nov 20177:00 amRNSAZN: Year-To-Date and Q3 2017 Results Announcement
1st Nov 20173:00 pmRNSTotal Voting Rights
1st Nov 20177:03 amRNSASTRAZENECA AND ASPEN COMPLETE ANAESTHETICS DEAL
1st Nov 20177:00 amRNSAstraZeneca tralokinumab update in severe asthma
31st Oct 20175:05 pmRNSUS FDA approves AstraZeneca's Calquence for MCL
23rd Oct 20177:05 amRNSAZ and MSD rapidly advance Lynparza in Japan
23rd Oct 20177:00 amRNSUS FDA approves Bydureon BCise for type-2 diabetes
18th Oct 20177:00 amRNSFDA Priority Review for Lynparza in breast cancer
17th Oct 20177:00 amRNSFDA accepts sBLA file for Imfinzi; priority review
9th Oct 20177:00 amRNSFDA grants Tagrisso BTD for 1st-line EGFR nsclc
2nd Oct 20173:00 pmRNSTotal Voting Rights
26th Sep 201712:00 pmRNSDirector/PDMR Shareholding
14th Sep 20177:00 amRNSAspen acquires remaining rights to AZ anaesthetics
11th Sep 20177:00 amRNSTagrisso potential standard of care in lung cancer
151617181920212223

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
XAAA
Faaa Clo Ghga
LSE
0.07%
HLMA
Halma
LSE
-4.39%
T52
3 3/4% 52
LSE
0.08%
LSL
Lsl Prop
LSE
-1.40%
DOM
Dominos
LSE
0.90%
Trending
ITM
Itm Power
LSE
-10.85%
GST
GSTechnologies
LSE
8.11%
PPP
Pennpetro Energy
LSE
0.00%
EZJ
easyJet
LSE
0.34%
NANO
Nanoco
LSE
-10.69%